CMPX Stock Summary and Trading Ideas (Compass Therapeutics | NASDAQ:CMPX)

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Compass Therapeutics trades on the NASDAQ stock market under the symbol CMPX.

As of March 10, 2025, CMPX stock price declined to $2.37 with 575,580 million shares trading.

CMPX has a beta of 2.36, meaning it tends to be more sensitive to market movements. CMPX has a correlation of 0.12 to the broad based SPY ETF.

CMPX has a market cap of $326.09 million. This is considered a Small Cap stock.

In the last 3 years, CMPX traded as high as $5.65 and as low as $.77.

The top ETF exchange traded funds that CMPX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

CMPX has outperformed the market in the last year with a return of +23.4%, while the SPY ETF gained +10.3%. In the last 3 month period, CMPX beat the market returning +42.8%, while SPY returned -7.4%. However, in the most recent 2 weeks CMPX has underperformed the stock market by returning -18.8%, while SPY returned -6.6%.

CMPX support price is $2.52 and resistance is $2.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMPX shares will trade within this expected range on the day.